<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Goncalves BMF</submitter><funding>Universidade de Coimbra</funding><funding>Programa Operacional Regional do Centro</funding><funding>European Regional Development Fund</funding><pagination>313-331</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9945870</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(2)</volume><pubmed_abstract>Arjunolic acid (AA) is a pentacyclic triterpenoid with promising anticancer properties. A series of novel AA derivatives containing a pentameric A-ring with an enal moiety, combined with additional modifications at C-28, were designed and prepared. The biological activity on the viability of human cancer and non-tumor cell lines was evaluated in order to identify the most promising derivatives. Additionally, a preliminary study of the structure-activity relationship was carried out. The most active derivative, derivative 26, also showed the best selectivity between malignant cells and non-malignant fibroblasts. For compound 26, the anticancer molecular mechanism of action in PANC-1 cells was further studied and the results showed that this derivative induced a cell-cycle arrest at G0/G1 ph</pubmed_abstract><journal>RSC medicinal chemistry</journal><pubmed_title>Design, synthesis, and biological evaluation of new arjunolic acid derivatives as anticancer agents.</pubmed_title><pmcid>PMC9945870</pmcid><funding_grant_id>CENTRO-01-0247-FEDER-003269</funding_grant_id><pubmed_authors>Salvador JAR</pubmed_authors><pubmed_authors>Goncalves BMF</pubmed_authors><pubmed_authors>Silvestre SM</pubmed_authors><pubmed_authors>Mendes VIS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Design, synthesis, and biological evaluation of new arjunolic acid derivatives as anticancer agents.</name><description>Arjunolic acid (AA) is a pentacyclic triterpenoid with promising anticancer properties. A series of novel AA derivatives containing a pentameric A-ring with an enal moiety, combined with additional modifications at C-28, were designed and prepared. The biological activity on the viability of human cancer and non-tumor cell lines was evaluated in order to identify the most promising derivatives. Additionally, a preliminary study of the structure-activity relationship was carried out. The most active derivative, derivative 26, also showed the best selectivity between malignant cells and non-malignant fibroblasts. For compound 26, the anticancer molecular mechanism of action in PANC-1 cells was further studied and the results showed that this derivative induced a cell-cycle arrest at G0/G1 ph</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2026-03-18T14:08:16.32Z</modification><creation>2025-08-23T03:09:06.433Z</creation></dates><accession>S-EPMC9945870</accession><cross_references><pubmed>36846362</pubmed><doi>10.1039/d2md00275b</doi></cross_references></HashMap>